研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology,WuHan,Hubei,China,430030
研究目的：
Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.
